| Initial genome sequencing and analysis of multiple myeloma MA Chapman, MS Lawrence, JJ Keats, K Cibulskis, C Sougnez, ... Nature 471 (7339), 467-472, 2011 | 1691 | 2011 |
| Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma AK Stewart, SV Rajkumar, MA Dimopoulos, T Masszi, I Špička, A Oriol, ... New England Journal of Medicine 372 (2), 142-152, 2015 | 1581 | 2015 |
| Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma JJ Keats, R Fonseca, M Chesi, R Schop, A Baker, WJ Chng, S Van Wier, ... Cancer cell 12 (2), 131-144, 2007 | 1212 | 2007 |
| International Myeloma Working Group molecular classification of multiple myeloma: spotlight review R Fonseca, PL Bergsagel, J Drach, J Shaughnessy, N Gutierrez, ... Leukemia 23 (12), 2210-2221, 2009 | 1182 | 2009 |
| Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy JG Lohr, P Stojanov, SL Carter, P Cruz-Gordillo, MS Lawrence, D Auclair, ... Cancer cell 25 (1), 91-101, 2014 | 1099 | 2014 |
| Genetics and cytogenetics of multiple myeloma: a workshop report R Fonseca, B Barlogie, R Bataille, C Bastard, PL Bergsagel, M Chesi, ... Cancer research 64 (4), 1546-1558, 2004 | 934 | 2004 |
| Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1 … JG Berdeja, D Madduri, SZ Usmani, A Jakubowiak, M Agha, AD Cohen, ... The Lancet 398 (10297), 314-324, 2021 | 893 | 2021 |
| A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma DS Siegel, T Martin, M Wang, R Vij, AJ Jakubowiak, S Lonial, S Trudel, ... Blood, The Journal of the American Society of Hematology 120 (14), 2817-2825, 2012 | 808 | 2012 |
| Clonal competition with alternating dominance in multiple myeloma JJ Keats, M Chesi, JB Egan, VM Garbitt, SE Palmer, E Braggio, ... Blood, The Journal of the American Society of Hematology 120 (5), 1067-1076, 2012 | 778 | 2012 |
| Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report A Palumbo, S Bringhen, MV Mateos, A Larocca, T Facon, SK Kumar, ... Blood, The Journal of the American Society of Hematology 125 (13), 2068-2074, 2015 | 766 | 2015 |
| Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma H Quach, D Ritchie, AK Stewart, P Neeson, S Harrison, MJ Smyth, ... Leukemia 24 (1), 22-32, 2010 | 738 | 2010 |
| Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide YX Zhu, E Braggio, CX Shi, LA Bruins, JE Schmidt, S Van Wier, XB Chang, ... Blood, The Journal of the American Society of Hematology 118 (18), 4771-4779, 2011 | 682 | 2011 |
| Oral selinexor–dexamethasone for triple-class refractory multiple myeloma A Chari, DT Vogl, M Gavriatopoulou, AK Nooka, AJ Yee, CA Huff, ... New England Journal of Medicine 381 (8), 727-738, 2019 | 593 | 2019 |
| Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma S Kumar, I Flinn, PG Richardson, P Hari, N Callander, SJ Noga, ... Blood, The Journal of the American Society of Hematology 119 (19), 4375-4382, 2012 | 558 | 2012 |
| Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides JB Egan, CX Shi, W Tembe, A Christoforides, A Kurdoglu, S Sinari, ... Blood, The Journal of the American Society of Hematology 120 (5), 1060-1066, 2012 | 504 | 2012 |
| Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial CB Reeder, DE Reece, V Kukreti, C Chen, S Trudel, J Hentz, B Noble, ... Leukemia 23 (7), 1337-1341, 2009 | 469 | 2009 |
| Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial WF Clark, AK Stewart, GA Rock, M Sternbach, DM Sutton, BJ Barrett, ... Annals of internal medicine 143 (11), 777-784, 2005 | 445 | 2005 |
| Genetic aberrations and survival in plasma cell leukemia RE Tiedemann, N Gonzalez-Paz, RA Kyle, R Santana-Davila, ... Leukemia 22 (5), 1044-1052, 2008 | 443 | 2008 |
| AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies M Chesi, DF Robbiani, M Sebag, WJ Chng, M Affer, R Tiedemann, ... Cancer cell 13 (2), 167-180, 2008 | 439 | 2008 |
| Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis JR Mikhael, SR Schuster, VH Jimenez-Zepeda, N Bello, J Spong, ... Blood, The Journal of the American Society of Hematology 119 (19), 4391-4394, 2012 | 418 | 2012 |
